Schizophrenia Research

Schizophrenia is a chronic, debilitating mental disorder affecting 1-2% of the global population. Symptoms are split into two types; 'positive' symptoms, including delusions and hallucinations, and 'negative' symptoms, including anhedonia and lack of motivation. Studies suggest that genetics, early environment, neurobiology, psychological and social processes are important contributory factors; some recreational and prescription drugs appear to cause or worsen symptoms. Several neurobiological alterations in brain structure, physiology and neurochemistry have been documented, along with an ever-increasing list of susceptibility genes.

Schizophrenia Research Products Targets

Products for Schizophrenia Research - Page 68

Cat.No. Product Name Information/Activity
BCC1487 Clozapine N-oxide (CNO) Activator of muscarinic DREAADs,Clozapine N-oxide is a pharmacologically inert metabolite of Clozapine, which is a potent <b>5-HT1C</b> receptor antagonist.
BCC5702 ACPT-I 194918-76-8
BCC7344 AMN 082 dihydrochloride The first selective mGlu<sub>7</sub> agonist
BCC6550 L-AP4 L-APB is a potent and specific agonist for the group III mGluRs, with EC50s of 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6 and mGlu7 receptors, respectively.
BCC7865 Cinnabarinic acid 606-59-7
BCC7045 (RS)-3,4-DCPG 176796-64-8
BCC7012 (S)-3,4-DCPG 201730-11-2
BCC7652 NPEC-caged-(S)-3,4-DCPG 1257323-85-5
BCC6578 O-Phospho-L-serine O-Phospho-L-serine is the immediate precursor to L-serine in the serine synthesis pathway, and an agonist at the group III mGluR receptors (mGluR4, mGluR6, mGluR7, and mGluR8); O-Phospho-L-serine also acts as a weak antagonist for mGluR1 and a potent antagonist for mGluR2.
BCC6975 (RS)-PPG (RS)-PPG is a potent and selective agonist for group III mGluRs. The EC50s of 5.2 μM, 4.7 μM, 185 μM, and 0.2 μM for hmGluR4a, hmGluR6, hmGluR7b, and hmGluR8a, respectively. Anticonvulsive and neuroprotective activity.